|
LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety.
Why Antibody Therapies Fail in Late-Stage Testing
Antibody therapies work in part by binding to Fcγ receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflammation. Since these receptors are different between species, human therapies tested in standard laboratory mice give unreliable efficacy results or miss potential safety risks. These discrepancies cause expensive late-stage failures and slow patient access to new therapies.
A New Mouse Model with Humanized Fcγ Receptors Set to Become a Gamechanger
A new study published in Science Immunology showed that an innovative mouse model developed by genOway, genO-hFcγR, helps scientists better predict the efficacy and safety of therapeutic antibodies in humans. The model allows scientists to rank different antibody candidates by how they are likely to perform, measure how effectively they target specific immune cells, and evaluate their potential to slow disease progression. This gives researchers key early insights to guide decisions and accelerate drug development.
Video on genO-hFcγR mice: https://www.youtube.com/watch?v=H7xO-xGJV8Q
Read the publication: https://www.science.org/doi/10.1126/sciimmunol.ady7328
A Complex Scientific Challenge Achieved Through International Collaboration
Due to the species-specific nature of Fcγ receptors, developing this model demanded multidisciplinary expertise in mouse genetics, antibody biology, and human immunology.
The achievement was made possible through an international consortium of leading biopharmaceutical partners, led by genOway, who combined their knowledge to co-develop and co-validate the genO-hFcγR mouse model. Consortium members included genOway (France), a company specializing in developing highly predictive preclinical models; argenx (Belgium), a pioneer in Fc-engineering and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University (Belgium), a leading immunology institute, to publish the study in Science Immunology. In this study, scientists at VIB-Ghent University mapped Fc receptor expression and regulation to illustrate how the new mouse model could be used to better model human disease and coordinated the publication of the work.
A Unique Solution Available for the Scientific Community
The genO–hFcγR model builds on a previous mouse model developed in 2008 by genOway and its scientific partners, in which multiple FcγR genes were humanized. Since its launch to the scientific community in 2024, genO-hFcγR has been adopted to advance preclinical programs of biopharmaceutical companies and nonprofit organizations, including the Gates Foundation, as one of the foundation's global health research initiatives.
Read the Gates Foundation press release at https://www.genoway.com/news-events/genoway-gates-foundation-2025
About genOway
genOway is a biotechnology company that provides highly predictive preclinical models and solutions to biopharmaceutical companies, CROs and academic institutions to bridge the gap between preclinical findings and clinical success. More information at genoway.com.
Contact
Ana REZA
Marketing Communications Manager
reza@genoway.com
LYON, France, Feb. 26, 2026 /PRNewswire/ -- Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety.
Why Antibody Therapies Fail in Late-Stage Testing
Antibody therapies work in part by binding to Fcγ receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflammation. Since these receptors are different between species, human therapies tested in standard laboratory mice give unreliable efficacy results or miss potential safety risks. These discrepancies cause expensive late-stage failures and slow patient access to new therapies.
A New Mouse Model with Humanized Fcγ Receptors Set to Become a Gamechanger
A new study published in Science Immunology showed that an innovative mouse model developed by genOway, genO-hFcγR, helps scientists better predict the efficacy and safety of therapeutic antibodies in humans. The model allows scientists to rank different antibody candidates by how they are likely to perform, measure how effectively they target specific immune cells, and evaluate their potential to slow disease progression. This gives researchers key early insights to guide decisions and accelerate drug development.
Video on genO-hFcγR mice: https://www.youtube.com/watch?v=H7xO-xGJV8Q
Read the publication: https://www.science.org/doi/10.1126/sciimmunol.ady7328
A Complex Scientific Challenge Achieved Through International Collaboration
Due to the species-specific nature of Fcγ receptors, developing this model demanded multidisciplinary expertise in mouse genetics, antibody biology, and human immunology.
The achievement was made possible through an international consortium of leading biopharmaceutical partners, led by genOway, who combined their knowledge to co-develop and co-validate the genO-hFcγR mouse model. Consortium members included genOway (France), a company specializing in developing highly predictive preclinical models; argenx (Belgium), a pioneer in Fc-engineering and FcRn biology; Innate Pharma (France), a leader in natural killer cell-based immunotherapies; and Vir Biotechnology (USA), focused on the development of immunotherapies; among other members. The group collaborated with VIB-Ghent University (Belgium), a leading immunology institute, to publish the study in Science Immunology. In this study, scientists at VIB-Ghent University mapped Fc receptor expression and regulation to illustrate how the new mouse model could be used to better model human disease and coordinated the publication of the work.
A Unique Solution Available for the Scientific Community
The genO–hFcγR model builds on a previous mouse model developed in 2008 by genOway and its scientific partners, in which multiple FcγR genes were humanized. Since its launch to the scientific community in 2024, genO-hFcγR has been adopted to advance preclinical programs of biopharmaceutical companies and nonprofit organizations, including the Gates Foundation, as one of the foundation's global health research initiatives.
Read the Gates Foundation press release at https://www.genoway.com/news-events/genoway-gates-foundation-2025
About genOway
genOway is a biotechnology company that provides highly predictive preclinical models and solutions to biopharmaceutical companies, CROs and academic institutions to bridge the gap between preclinical findings and clinical success. More information at genoway.com.
Contact
Ana REZA
Marketing Communications Manager
reza@genoway.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
genOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse Model
SINGAPORE, Feb. 26, 2026 /PRNewswire/ -- Sgcarmart, Singapore's most trusted automotive platform, is launching Beyond Motion, its first ever experience-driven electrified mobility showcase, taking place on March 21–22, 2026 at the Suntec Convention Centre, Halls 403–404. Designed for prospective EV buyers, car enthusiasts, industry professionals, and anyone curious about the future of electric mobility, Beyond Motion will bring together major brands, experts, and ecosystem partners for two days of discovery, education, and hands-on engagement.
Singapore's EV adoption has accelerated rapidly, with 2025 marking the first year that fully electric vehicles became the top choice among new passenger car registrations, representing 45% of the market.
"Electrification, new energy, digitalisation, shifting consumer expectations and global competition are accelerating the transformation of how people and goods move." said Shahrul Tahir, CEO of Sgcarmart. "Beyond Motion creates the ideal environment for consumers and industry stakeholders to explore the electrified future together."
A First of Its Kind EV Experience for All
Over two days, Beyond Motion will offer an interactive, accessible, and highly engaging programme designed to simplify EV adoption and introduce attendees to the latest advancements in electrified mobility:
Multi Brand EV Showcase Brand EV Showcase
Visitors can explore, compare, and experience the latest electric and hybrid models under one roof. With over eight exhibiting brands, attendees can expect new model launches, technology showcases, and event exclusive promotions.
Education Hubs and Learning Zones
Expert led sessions will cover EV ownership fundamentals, charging infrastructure, battery innovation, sustainability, and future mobility trends. Specialists will be available to address practical questions on daily usage, charging routines, and lifestyle considerations.
Industry Conversations & Expert Panels
Beyond Motion will host policymakers, charging providers, OEMs, and mobility innovators for panel discussions, keynote conversations, and moderated sessions. These dialogues will explore Singapore's electrification roadmap, infrastructure development, technology shifts, and opportunities for collaboration across the mobility ecosystem.
Interactive Experiences and Prizes
Attendees can participate in hands on activities, discover new technologies, and complete a stamp rally to redeem event exclusive prizes, making the experience engaging for first time EV explorers and experienced industry professionals alike
"Through immersive and interactive experiences, we hope to bridge the gap for those considering the transition to electric mobility, while helping shape how the wider ecosystem continues to evolve," said Yau Fun Heng, COO of Sgcarmart.
Registration Now Open
Admission to Beyond Motion is free with registration. Members of the public are encouraged to register early to secure access to sessions, activities, and prize opportunities.
Event Details
- Event: Beyond Motion
- Dates: 21–22 March 2026
- Venue: Suntec Convention Centre, Halls 403–404
- Admission: Free with registration
About Sgcarmart
Sgcarmart is Singapore's No. 1 car platform. With over 30,000 listings, it hosts the largest database of new and used cars, supporting approximately 70% of all second-hand car transactions in Singapore. The platform receives more than 1.6 million users every month and provides a comprehensive suite of value-added car ownership and transactional services.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Sgcarmart Announces "Beyond Motion" Singapore's First Immersive Mobility Experience on March 21-22, 2026, Featuring Leading EV Brands, Industry Experts, and Future Forward Talks
